Florealis
Financials
Estimates*
EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
% growth | 1844 % | 25 % | 125 % | 72 % | (14 %) | - | - |
EBITDA | - | - | (1.2m) | (1.2m) | (<1m) | (<1m) | - |
% EBITDA margin | - | - | (309 %) | (187 %) | (126 %) | (116 %) | - |
Profit | (<1m) | (<1m) | (1.2m) | (1.4m) | (<1m) | (<1m) | - |
% profit margin | (265 %) | (358 %) | (320 %) | (207 %) | (146 %) | (143 %) | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$3.8m | Early VC | ||
€670k Valuation: €9.3m 13.9x EV/LTM Revenues -7.5x EV/LTM EBITDA | Seed | ||
Total Funding | CAD6.2m |
Related Content
Recent News about Florealis
EditFlorealis operates in the healthcare sector, specializing in the development and distribution of herbal medicines and medical devices aimed at treating mild diseases. The company serves consumers seeking natural and effective solutions for conditions such as sleep disorders, anxiety, and intimate health issues. Florealis primarily operates in the Icelandic and Swedish markets, offering products like Sefitude, a herbal medicine for sleep disorders and mild nervous tension, and various intimate health products including Lyngonia, Smaronia, Rosonia, and Liljonia. These products are available over the counter in pharmacies and online, providing easy access to consumers.
The business model of Florealis revolves around the development, approval, and sale of herbal medicines and medical devices. Revenue is generated through direct sales to consumers via online platforms and through partnerships with pharmacies. By focusing on natural ingredients and addressing common health issues, Florealis taps into the growing market demand for alternative and complementary medicine.
Keywords: herbal medicine, sleep disorders, anxiety relief, intimate health, Valerian root, over-the-counter, Iceland, Sweden, natural remedies, mild diseases.